tiprankstipranks
Trending News
More News >
Cabaletta Bio (CABA)
NASDAQ:CABA
US Market

Cabaletta Bio (CABA) Stock Forecast & Price Target

Compare
1,069 Followers
See the Price Targets and Ratings of:

CABA Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Cabaletta
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CABA Stock 12 Month Forecast

Average Price Target

$15.43
▲(522.18%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Cabaletta Bio in the last 3 months. The average price target is $15.43 with a high forecast of $25.00 and a low forecast of $3.00. The average price target represents a 522.18% change from the last price of $2.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","26":"$26","6.5":"$6.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.5,13,19.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,3.0769230769230766,4.903846153846153,6.730769230769231,8.557692307692307,10.384615384615385,12.211538461538462,14.038461538461538,15.865384615384615,17.692307692307693,19.51923076923077,21.346153846153847,23.173076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,2.3407692307692307,3.4315384615384614,4.522307692307692,5.613076923076923,6.703846153846154,7.794615384615384,8.885384615384615,9.976153846153846,11.066923076923077,12.157692307692308,13.248461538461537,14.339230769230769,{"y":15.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.3846153846153846,1.5192307692307692,1.6538461538461537,1.7884615384615383,1.923076923076923,2.0576923076923075,2.1923076923076925,2.3269230769230766,2.4615384615384617,2.596153846153846,2.730769230769231,2.8653846153846154,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.82,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.19,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$15.43Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CABA
Derek ArchilaWells Fargo
Wells Fargo
$3
Hold
20.97%
Upside
Reiterated
05/16/25
Cabaletta Bio: Hold Rating Amid Cash Constraints and Regulatory Challenges
H.C. Wainwright Analyst forecast on CABA
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$25
Buy
908.06%
Upside
Reiterated
05/16/25
Cabaletta Bio's Strategic Advancements and Trial Successes Drive Buy Rating
Citi
$17$13
Buy
424.19%
Upside
Reiterated
05/16/25
Cabaletta Bio price target lowered to $13 from $17 at CitiCabaletta Bio price target lowered to $13 from $17 at Citi
Guggenheim Analyst forecast on CABA
Yatin SunejaGuggenheim
Guggenheim
$23$25
Buy
908.06%
Upside
Reiterated
05/15/25
Cabaletta Bio price target raised to $25 from $23 at GuggenheimCabaletta Bio price target raised to $25 from $23 at Guggenheim
William Blair Analyst forecast on CABA
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/15/25
William Blair Keeps Their Buy Rating on Cabaletta Bio (CABA)
TD Cowen Analyst forecast on CABA
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
05/15/25
Cabaletta Bio's Strong Financial Position and Strategic Clinical Progress Justify Buy Rating
UBS
$10$7
Buy
182.26%
Upside
Reiterated
04/01/25
Cabaletta Bio price target lowered to $7 from $10 at UBSCabaletta Bio price target lowered to $7 from $10 at UBS
Morgan Stanley Analyst forecast on CABA
Michael UlzMorgan Stanley
Morgan Stanley
$30$22
Buy
787.10%
Upside
Reiterated
04/01/25
Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating
Stifel Nicolaus Analyst forecast on CABA
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$26$13
Buy
424.19%
Upside
Reiterated
03/31/25
Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Connect Biopharma Holdings (CNTB)
Evercore ISI
$6
Hold
141.94%
Upside
Downgraded
12/20/24
Cabaletta Bio downgraded to In Line from Outperform at Evercore ISICabaletta Bio downgraded to In Line from Outperform at Evercore ISI
Cantor Fitzgerald Analyst forecast on CABA
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$50
Buy
1916.13%
Upside
Reiterated
06/20/24
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Cabaletta Bio (NASDAQ: CABA)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CABA
Derek ArchilaWells Fargo
Wells Fargo
$3
Hold
20.97%
Upside
Reiterated
05/16/25
Cabaletta Bio: Hold Rating Amid Cash Constraints and Regulatory Challenges
H.C. Wainwright Analyst forecast on CABA
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$25
Buy
908.06%
Upside
Reiterated
05/16/25
Cabaletta Bio's Strategic Advancements and Trial Successes Drive Buy Rating
Citi
$17$13
Buy
424.19%
Upside
Reiterated
05/16/25
Cabaletta Bio price target lowered to $13 from $17 at CitiCabaletta Bio price target lowered to $13 from $17 at Citi
Guggenheim Analyst forecast on CABA
Yatin SunejaGuggenheim
Guggenheim
$23$25
Buy
908.06%
Upside
Reiterated
05/15/25
Cabaletta Bio price target raised to $25 from $23 at GuggenheimCabaletta Bio price target raised to $25 from $23 at Guggenheim
William Blair Analyst forecast on CABA
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/15/25
William Blair Keeps Their Buy Rating on Cabaletta Bio (CABA)
TD Cowen Analyst forecast on CABA
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
05/15/25
Cabaletta Bio's Strong Financial Position and Strategic Clinical Progress Justify Buy Rating
UBS
$10$7
Buy
182.26%
Upside
Reiterated
04/01/25
Cabaletta Bio price target lowered to $7 from $10 at UBSCabaletta Bio price target lowered to $7 from $10 at UBS
Morgan Stanley Analyst forecast on CABA
Michael UlzMorgan Stanley
Morgan Stanley
$30$22
Buy
787.10%
Upside
Reiterated
04/01/25
Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating
Stifel Nicolaus Analyst forecast on CABA
Benjamin BurnettStifel Nicolaus
Stifel Nicolaus
$26$13
Buy
424.19%
Upside
Reiterated
03/31/25
Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Connect Biopharma Holdings (CNTB)
Evercore ISI
$6
Hold
141.94%
Upside
Downgraded
12/20/24
Cabaletta Bio downgraded to In Line from Outperform at Evercore ISICabaletta Bio downgraded to In Line from Outperform at Evercore ISI
Cantor Fitzgerald Analyst forecast on CABA
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$50
Buy
1916.13%
Upside
Reiterated
06/20/24
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Cabaletta Bio (NASDAQ: CABA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cabaletta Bio

1 Month
xxx
Success Rate
5/10 ratings generated profit
50%
Average Return
+2.56%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.56% per trade.
3 Months
xxx
Success Rate
14/23 ratings generated profit
61%
Average Return
+80.68%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +80.68% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
13/23 ratings generated profit
57%
Average Return
+170.14%
reiterated a buy rating 24 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +170.14% per trade.
2 Years
xxx
Success Rate
4/10 ratings generated profit
40%
Average Return
-22.63%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -22.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CABA Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
8
3
4
7
8
Buy
4
2
2
2
3
Hold
2
2
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
7
7
10
13
In the current month, CABA has received 11 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CABA average Analyst price target in the past 3 months is 15.43.
Each month's total comprises the sum of three months' worth of ratings.

CABA Financial Forecast

CABA Earnings Forecast

Next quarter’s earnings estimate for CABA is -$0.65 with a range of -$0.76 to -$0.11. The previous quarter’s EPS was ―. CABA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year CABA has Preformed in-line its overall industry.
Next quarter’s earnings estimate for CABA is -$0.65 with a range of -$0.76 to -$0.11. The previous quarter’s EPS was ―. CABA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year CABA has Preformed in-line its overall industry.
No data currently available

CABA Sales Forecast

Next quarter’s sales forecast for CABA is $4.17M with a range of $0.00 to $25.00M. The previous quarter’s sales results were ―. CABA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year CABA has Preformed in-line its overall industry.
Next quarter’s sales forecast for CABA is $4.17M with a range of $0.00 to $25.00M. The previous quarter’s sales results were ―. CABA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year CABA has Preformed in-line its overall industry.

CABA Stock Forecast FAQ

What is CABA’s average 12-month price target, according to analysts?
Based on analyst ratings, Cabaletta Bio’s 12-month average price target is 15.43.
    What is CABA’s upside potential, based on the analysts’ average price target?
    Cabaletta Bio has 522.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CABA a Buy, Sell or Hold?
          Cabaletta Bio has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Cabaletta Bio’s price target?
            The average price target for Cabaletta Bio is 15.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $3.00. The average price target represents 522.18% Increase from the current price of $2.48.
              What do analysts say about Cabaletta Bio?
              Cabaletta Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of CABA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis